Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
Remo PanaccioneSilvio DaneseWilliam J SandbornChristopher D O'BrienYiying ZhouHongyan ZhangOmoniyi J AdedokunIlia TikhonovStephan TarganMaria T AbreuTadakazu HisamatsuEllen J ScherlRupert W LeongDavid S RowbothamRamesh Pulendran ArasaradnamBruce E SandsColleen MaranoPublished in: Alimentary pharmacology & therapeutics (2020)
The efficacy of ustekinumab in patients with UC was sustained through 92 weeks. No new safety signals were observed (ClinicalTrials.gov number, NCT02407236).